VCM
GALT icon

Vivaldi Capital Management’s Galectin Therapeutics GALT Stock Holding History

Vivaldi Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-258,584
Closed -$721K – 81
2026
Q1 		$721K Buy
258,584
+54,514
+27% +$166K 0.1% 127
2025
Q4 		$849K Sell
204,070
-51,682
-20% -$272K 0.12% 115
2025
Q3 		$1.08M Buy
255,752
+83,309
+48% +$313K 0.15% 106
2025
Q2 		$364K Buy
172,443
+116,815
+210% +$175K 0.05% 196
2025
Q1 		$67.9K Buy
55,628
+10,000
+22% +$14K 0.01% 279
2024
Q4 		$55.7K Buy
45,628
+21,596
+90% +$51.8K 0.01% 283
2024
Q3 		$66.1K Hold
24,032
– – 0.02% 224
2024
Q2 		$54.3K Hold
24,032
– – 0.02% 228
2024
Q1 		$72.8K Buy
24,032
+4,771
+25% +$9.03K 0.02% 219
2023
Q4 		$32.6K Hold
19,261
– – 0.01% 219
2023
Q3 		$37K Hold
19,261
– – 0.01% 193
2023
Q2 		$27.7K Hold
19,261
– – 0.01% 200
2023
Q1 		$40.4K Hold
19,261
– – 0.01% 200
2022
Q4 		$22.5K Hold
19,261
– – 0.01% 241
2022
Q3 		$30K Buy
19,261
+2,183
+13% +$4.08K 0.01% 220
2022
Q2 		$22K Hold
17,078
– – 0.01% 216
2022
Q1 		$23K Buy
17,078
+6,410
+60% +$12.4K 0.01% 213
2021
Q4 		$22K Hold
10,668
– – 0.01% 207
2021
Q3 		$41K Hold
10,668
– – 0.01% 333
2021
Q2 		$36K Hold
10,668
– – 0.01% 343
2021
Q1 		$45K Sell
10,668
-4,771
-31% -$10.7K 0.01% 357
2020
Q4 		$35K Hold
15,439
– – 0.01% 302
2020
Q3 		$42K Hold
15,439
– – 0.01% 275
2020
Q2 		$40K Buy
15,439
+4,771
+45% +$12K 0.01% 259
2020
Q1 		$21K Hold
10,668
– – ﹤0.01% 195
2019
Q4 		$31K Hold
10,668
– – 0.01% 209
2019
Q3 		$39K Hold
10,668
– – 0.01% 216
2019
Q2 		$44K Buy
+10,668
New +$46.2K 0.01% 227

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vivaldi Capital Management's GALT Position: Q2 2026 in Review

Vivaldi Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 258,584 shares — an estimated $721K sold.

Vivaldi Capital Management first reported a position in GALT in Q2 2019 and held it in 28 quarters. The position peaked at $1.08M in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Vivaldi Capital Management reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vivaldi Capital Management sold 258,584 Galectin Therapeutics shares in Q2 2026, an estimated $721K.
  • Vivaldi Capital Management first reported a position in Galectin Therapeutics in Q2 2019 and held it in 28 quarters.
  • Vivaldi Capital Management's Galectin Therapeutics position peaked at $1.08M in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Vivaldi Capital Management's 13F filing for Q2 2026.